Scleroderma

Scleroderma is a connective tissue disease of unknown etiology with a chronic course. Due to the deposition of the extracellular matrix such as collagen fibers, the disease can cause multiple system damages, leading to localized or diffuse skin thickening and fibrosis. Internal organs such as the digestive tract, lungs, heart, and kidneys may also be affected (systemic scleroderma). Common symptoms are Raynaud’s phenomenon, fatigue, musculoskeletal pain, etc. Scleroderma is more likely to infect women, and the most common age is 30 to 50 years. Although there is no cure for scleroderma, a variety of treatments can relieve symptoms and improve quality of life. Current research shows that scleroderma is associated with HLA-1 genes, as well as various immune cells and inflammatory factors such as B cells, Tn2, Th17, etc. may also participate in the pathogenesis.

Diagnosis of Scleroderma

The diagnosis methods of scleroderma are as follows:

• Blood routine. Patients with scleroderma may have dystrophic anemia, thrombocytosis, and some patients may also show leukopenia.
• Urine routine. Patients with scleroderma may show low specific gravity urine, elevated urine PH value, etc. Positive hematuria, tubular urine, and urine protein can be observed in some patients.
• Immunological examination. Systemic scleroderma antibody detection is very important and is one of the immune diseases with the most autoantibodies. Diagnosis and clinical classification are often based on the results, and patients' inflammatory indexes can be elevated. More than 90% of patients have positive antinuclear antibodies (ANA). Anti-Scl-70 antibodies and anticardiolipin antibodies (ACA) are also related to scleroderma.
• Imaging examination. X-ray, CT examination, ultrasound examination, myocardial MRI, esophageal barium meal examination, gastrointestinal endoscopy and so on can all be used for auxiliary diagnosis of scleroderma.
• Pathological examination. For the diagnosis of skin and internal organ damage, as well as clinical classification.

Advantages of Our Products

The scleroderma diagnostic kits developed by Creative Biogene adopts enzyme-linked immunoassay technology. In the past, it seems that some trace biologically active substances that are difficult to carry out in quality can be easily detected by our kits. Our products have high sensitivity, detection time, low cost, simple operation, and a variety of samples can be detected.

Creative Bioarray focuses on the field of diagnostic reagents for scleroderma. We are committed to providing the best products to accelerate the realization of customers' research goals. We look forward to working with you for your cooperation.

Please contact us for more details.

Reference

1. Asano, Y, et al. (2018). "Diagnostic criteria, severity classification and guidelines of localized scleroderma." The Journal of dermatology. 45.7: 755-780.